Vascular Biogenics Ltd represents values of innovation, dedication, and patient-centricity. As a leading biopharmaceutical company, Vascular Biogenics is committed to developing transformative therapies for patients suffering from cancer and other severe diseases. The company's corporate philosophy revolves around pushing the boundaries of scientific knowledge to create groundbreaking treatments that improve patient outcomes and quality of life. With a strong focus on research and development, Vascular Biogenics aims to revolutionize the healthcare industry by harnessing the potential of gene therapy and targeted drug delivery. By prioritizing patient well-being and scientific excellence, Vascular Biogenics strives to make a meaningful impact on global healthcare.

Vascular Biogenics Ltd is primarily present in the United States, Israel, and various countries in Europe. With headquarters in Israel, the company operates its research and development facilities, clinical trials, and manufacturing operations in these regions. By focusing on innovative therapies for cancer and inflammatory diseases, Vascular Biogenics Ltd has established a significant presence in the global biopharmaceutical market.

Vascular Biogenics Ltd has achieved several significant milestones in its journey. One notable accomplishment is the successful completion of phase 2 clinical trials for its leading product candidate, VB-111. The company has also entered into strategic collaborations with renowned pharmaceutical companies, such as Bristol-Myers Squibb and Intrexon Corporation, to further develop and market its innovative therapies. In addition, Vascular Biogenics Ltd has received regulatory approvals for its clinical trials in various countries, including the United States and Europe. These milestones showcase the company's commitment to advancing novel treatments and highlight its potential for growth and success in the biotechnology industry.

Vascular Biogenics Ltd, also known as VBL Therapeutics, is a clinical-stage biopharmaceutical company based in Israel. Founded in 2000, the company is focused on the development of novel treatments for cancer and inflammatory diseases. VBL Therapeutics utilizes its proprietary technology platform, Vascular Targeting System (VTS), to design and develop therapies that target specific types of blood vessels associated with various diseases. The company's lead product candidate, VB-111, is being evaluated in multiple clinical trials for different cancer indications. Vascular Biogenics has a strong commitment to innovation and addressing unmet medical needs, positioning itself as a significant player in the pharmaceutical industry.

The main competitors of Vascular Biogenics Ltd in the market include prominent companies such as Genentech, Novartis, Merck & Co., Pfizer, and Johnson & Johnson.

Vascular Biogenics Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Vascular Biogenics Ltd (VBL) is focused on developing and commercializing gene-based therapies for various types of cancer. VBL utilizes its proprietary technology platform, known as Vascular Targeting System (VTS), to design and develop novel biologics that target and disrupt the blood vessels supplying nutrients to tumors. By inhibiting tumor blood flow, VBL's therapies aim to starve cancer cells and impede their growth, ultimately leading to tumor regression. VBL collaborates with leading academic institutions and pharmaceutical companies to conduct preclinical and clinical trials, evaluate safety and efficacy, and advance the development of potential cancer treatments.

Vascular Biogenics의 P/E 비율은 -0.06입니다.

Vascular Biogenics의 P/S 비율은 1.81입니다.

Vascular Biogenics에 대한 AlleAktien 품질 점수는 6/10입니다.

예상되는 Vascular Biogenics 매출은 1.96 백만 USD입니다.

예상되는 Vascular Biogenics 이익은 -58.6 백만 USD입니다.

Vascular Biogenics Ltd is an Israeli company specializing in the development of therapeutic products for the treatment of cancer and inflammatory diseases. The company focuses on the development of antibodies and peptides that can specifically block or activate molecules in the body. It collaborates with various partners for the discovery and development of new therapeutics. Its core product is an oncology product called VBG-8264, which is in the clinical stage of development. Another promising product in its portfolio is VascuGel, which aims to reduce inflammation and promote wound healing. The company utilizes various distribution channels and partnerships to market its products globally. Vascular Biogenics aims to improve the health of patients worldwide through its innovative products.

Vascular Biogenics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Vascular Biogenics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Vascular Biogenics의 ISIN은 IL0011327454입니다.

Vascular Biogenics의 WKN은 A119YE입니다.

Vascular Biogenics의 티커는 VBLT입니다.

지난 12개월 동안 Vascular Biogenics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Vascular Biogenics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Vascular Biogenics의 현재 배당 수익률은 입니다.

Vascular Biogenics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Vascular Biogenics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Vascular Biogenics은 '건강' 섹터에 속합니다.

Vascular Biogenics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Vascular Biogenics는 0 USD를 배당금으로 지급했습니다.

Vascular Biogenics의 배당금은 USD에 지급됩니다.